Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: Implications for long-term drug efficacy and low extrapyramidal side-effects

International Journal of Neuropsychopharmacology

Volumn 12, Issue 7, 2009, Pages 941-952

  Han, Mei ^a,b   Huang, Xu Feng ^a,b   Deng, Chao ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Antipsychotics; Dopamine D2 receptor; Dopamine transporter; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HALOPERIDOL; MESSENGER RNA; OLANZAPINE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CAUDATE PUTAMEN; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; NIGRONEOSTRIATAL SYSTEM; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; SCHIZOPHRENIA; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRAIN; CAUDATE NUCLEUS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HALOPERIDOL; LIMBIC SYSTEM; NUCLEUS ACCUMBENS; PIPERAZINES; PUTAMEN; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION; VENTRAL TEGMENTAL AREA;

EID: 69349089612     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709009948     Document Type: Article

References (51)

1. Arjona A, Zhang SX, Adamson B, Wurtman RJ (2004). An animal model of antipsychotic-induced weight gain. Behavioural Brain Research 152, 121-127.
2. Bortolozzi A, Amargos-Bosch M, Adell A, Diaz-Mataix L, Serrats J, Pons S, Artigas F (2003). In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. European Journal of Neuroscience 18, 1235-1246.
3. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology & Experimental Therapeutics 302, 381-389. (Pubitemid 34680462)
4. Cassano GB, Fagiolini A, Lattanzi L, Monteleone P, Niolu C, Sacchetti E, Siracusano A, Vita A (2007). Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clinical Drug Investigation 27, 1-13.
5. Cooper GD, Pickavance LC, Wilding JPH, Halford JCG, Goudie AJ (2005). A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 181, 80-89.
6. Damask SP, Bovenkerk KA, de la Pena G, Hoversten KM, Peters DB, Valentine AM, Meador-Woodruff JH (1996). Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Research Molecular Brain Research 41, 241-249.
7. DeLeon A, Patel NC, Lynn Crismon M (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics 26, 649-666.
8. Deng C, Huang X-F (2005). Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. Journal of Neuroscience Research 81, 883-890.
9. Gross JR, Kelley AB, Johnson SA, Morgan DG (1991). Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice. Life Sciences 48, 1015-1022.
10. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. American Journal of Psychiatry 165, 988-995.
11. Han M, Deng C, Burne THJ, Newell KA, Huang X-F (2008a). Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 33, 569-580.
12. Han M, Newell K, Zavitsanou K, Deng C, Huang X-F (2008b). Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research 86, 457-464.
13. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T (2004). Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. Journal of Psychopharmacology 18, 375-383.
14. Huang X-F, Han M, Huang X, Zavitsanou K, Deng C (2006). Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behavioural Brain Research 171, 355-362.
15. Iversen LL (1971). Role of transmitter uptake mechanisms in synaptic neurotransmission. British Journal of Pharmacology 41, 571-591.
16. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA (2004). In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. European Journal of Pharmacology 483, 45-53.
17. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DNC (2005). Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 182, 220-231.
18. Kane JM, Meltzer HY, Carson Jr. WH, McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group (2007). Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 68, 213-223.
19. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 1081-1090.
20. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. Journal of Pharmacology & Experimental Therapeutics 305, 625-631.
21. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 157, 514-520.
22. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003). Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 6, 325-337.
23. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995). 7-(4-[4-(2,3-Dichlorphenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology & Experimental Therapeutics 274, 329-336.
24. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998). Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine (preclamol) in schizophrenia. Biological Psychiatry 43, 2-11.
25. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20, 612-627.
26. Li M, Budin R, Fleming AS, Kapur S (2005). Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology 181, 600-610. (Pubitemid 41480910)
27. Mailman RB (2007). GPCR functional selectivity has therapeutic impact. Trends in Pharmacological Sciences 28, 390-396.
28. McElvan JS, Schenk JO (1992). Blockade of dopamine autoreceptors by haloperidol and the apparent dynamics of potassium-simulated endogenous release of dopamine from and reuptake into striatal suspensions in the rat. Neuropharmacology 31, 649-659.
29. Meiergerd SM, Patterson AP, Schenk JO (1993). D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. Journal of Neurochemistry 61, 764-767.
30. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
31. Parsons LH, Schad CA, Justice JBJ (1993). Co-administration of the D2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine. Journal of Neurochemistry 60, 376-379.
32. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press.
33. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003). Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacology, Biochemistry and Behavior 75, 133-140.
34. Prosser ES, Csernansky JG, Hollister LE (1988). Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors. Life Sciences 43, 715-720.
35. Rogue P, Hanauer A, Zwiller J, Malviya AN, Vincendon G (1991). Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment. European Journal of Pharmacology 207, 165-168.
36. Roth RH (1979). Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Communications in Psychopharmacology 3, 429-425.
37. Sawa A, Snyder SH (2002). Schizophrenia: diverse approaches to a complex disease. Science 296, 692-695.
38. Schwabe K, Koch M (2007). Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology 191, 759-765.
39. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411.
40. Stephen M, Stahl MD (2003). Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Primary Care Companion to the Journal of Clinical Psychiatry 5 (Suppl. 3), 9-13.
41. Tarazi FI, Zhang K, Baldessarini RJ (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. Journal of Pharmacology & Experimental Therapeutics 297, 711-717.
42. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, Haddad PM, Hunter R, Taylor DM, Young AH (2005). Aripiprazole in schizophrenia: consensus guidelines. International Journal of Clinical Practice 59, 485-495.
43. Tyson PJ, Roberts KH, Mortimer AM (2004). Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? International Journal of Neuroscience 114, 593-611.
44. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007). Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32, 67-77.
45. Vohora D (2007). Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Current Opinion in Investigational Drugs 8, 531-538.
46. Wiley JL (2008). Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats. European Journal of Pharmacology 578, 216-221.
47. Wolf ME, Roth RH (1990). Autoreceptor Regulation of dopamine synthesis. Annals New York Academy of Sciences 604, 323-343.
48. Wolff MC, Wainscott DB, Nelson DL, Moore NA, Overshiner CD, Leander JD, Bymaster FP, Knitwoski K, McKinzie DL (2003). An in vivo assessment of aripiprazole, ziprasidone, risperidone and olanzapine in rat assays indicative of 5-HT1A and D2 receptor activity. Schizophrenia Research 60 (1, Suppl. 1), 119-120.
49. Wood M, Reavill C (2007). Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opinion on Investigational Drugs 16, 771-775.
50. Xiberas X, Martinot JL, Artiges E, Loc'H C, Maziere B, Paillere-Martinot ML (2001). Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 179, 503-508. (Pubitemid 34031674)
51. Zocchi A, Fabbri D, Heidbreder CA (2005). Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neuroscience Letters 387, 157-161.